HVAX (HVAX) fundamentals

HVAX is a listed company, part of the Engineering sector, listed on the NSE as HVAX (ISIN INE0TO501019). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.

What HVAX does

HVAX Technologies Limited is an India-based company. The Company is engaged in the business of turnkey projects on engineering, procurement and execution of controlled environment infrastructure and cleanrooms, design, engineering and consultancy services for pharma and healthcare companies. The Company builds viable infrastructure for biotech facilities, hospitals, and predominantly pharmaceutical facilities. Its products include clean room partition, HVAC systems, building management systems, clean room equipment, electrical HT/LT panels, containment technology, utility generation and distribution, pre-engineered buildings, and laboratories and furniture. The Company’s services include engineering consultancy, GAP analysis and validation, containment consultancy, technology transfer, and project feasibility. It has served over 200+ projects across 20 countries. Its customers are pharmaceutical companies. Its customers also include chemical companies, hospitals, and others.

Valuation and market data

Last close₹669.00
Market capitalisation₹161 crore
Enterprise value₹150 crore
P/E (TTM)3.54
Price to book2.23
Price to sales (TTM)0.40
Book value per share₹299.46
Dividend yield0.00%
SectorEngineering
Industry

Annual results

PeriodRevenueProfit before taxNet profitEPS
Mar 2026₹171 crore₹20 crore₹15 crore0.00

Figures are as reported (consolidated), in ₹ crore.

Shareholding pattern

As of Jun 2026:

Promoters66.7%
Foreign institutions (FII)8.9%
Mutual funds0.0%
Other domestic institutions1.1%
Retail and others23.4%

More on BreakPoint

FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.

Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.